| Re: Thursday Chat 11.18.10 |
Subject: Re: Thursday Chat 11.18.10 by pianoguy on 2010/11/18 13:22:54 Not to worry, Matt - out of sympathy, I didn't run, either. This got me to thinking: 8:16 AM Dendreon (DNDN) +8.9% premarket after a Medicare advisory committee votes to support government reimbursement for Dendreon's prostate cancer drug Provenge, which costs $93K and extends patients' lives by four months on average. The decision means Medicare will probably choose to cover the drug. Would you pay $93K to live 4 months? |
